Congenital amegakaryocytic thrombocytopenia
| Congenital amegakaryocytic thrombocytopenia | |
| Classification and external resources | |
| ICD-9 | 287.33, 287.5 |
|---|---|
| OMIM | 604498 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited disorder.[1][2][3]
Historical Perspective
Classification
Pathophysiology
Causes
The cause for this disorder appears to be a mutation in the gene for the TPO receptor, c-mpl, despite high levels of serum TPO.[4][5] In addition, there may be abnormalities with the central nervous system including the cerebrum and cerebellum which could cause symptoms.[4]
Differentiating Congenital amegakaryocytic thrombocytopenia from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
The primary manifestations are thrombocytopenia and megakaryocytopenia, or low numbers of platelets and megakaryocytes. There is an absence of megakaryocytes in the bone marrow with no associated physical abnormalities.[6]
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
The primary treatment for CAMT is bone marrow transplantation.[7]
Bone Marrow/Stem Cell Transplant is the only thing that ultimately cures this genetic disease. Frequent platelet transfusions are required to ensure that platelet levels do not fall to dangerous levels, although this is not always the case. It is known for patients to continue to create very small numbers of platelets over time.
Surgery
Prevention
See also
References
- ↑ Ballmaier M, Germeshausen M, Schulze H, et al. (January 2001). "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia". Blood. 97 (1): 139–46. doi:10.1182/blood.V97.1.139. PMID 11133753.
- ↑ Germeshausen M, Ballmaier M, Welte K (March 2006). "MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease". Hum. Mutat. 27 (3): 296. doi:10.1002/humu.9415. PMID 16470591.
- ↑ Rose MJ, Nicol KK, Skeens MA, Gross TG, Kerlin BA (June 2008). "Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics". Pediatr Blood Cancer. 50 (6): 1263–5. doi:10.1002/pbc.21453. PMID 18240171.
- ↑ 4.0 4.1 Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T (1999). "Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia". Proc. Natl. Acad. Sci. 96 (6): 3133–6. doi:10.1073/pnas.96.6.3132. PMC 15907. PMID 10077649.
- ↑ Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K (2001). "C-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia". Blood. 97 (1): 139–46. doi:10.1182/blood.V97.1.139. PMID 11133753.
- ↑ Freedman MH, Estrov Z (1990). "Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect". Am. J. Pediatr. Hematol. Oncol. 12 (2): 225–230. doi:10.1097/00043426-199022000-00020. PMID 2378417.
- ↑ King S, Germeshausen M, Strauss G, Welte K, Ballmaier M (December 2005). "Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients". Br. J. Haematol. 131 (5): 636–44. doi:10.1111/j.1365-2141.2005.05819.x. PMID 16351641.
External links
- Amegakaryocytic Thrombocytopenia research study of Inherited Bone Marrow Failure Syndromes (IBMFS)
- CAMT Specific Infant Bone Marrow Transplant Journal - One of the few non Medical Research related sources on the web with some information on CAMT. There appears to be no generic resource for CAMT patients on the web, and this is potentially due to the rariety of the disease
- https://www.facebook.com/topic.php?uid=38970584460&topic=6387#/group.php?gid=38970584460 This is the closest thing to a 'support group' for this condition.